Clinical Trial Update: Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance [Phase 2]

View source ↗

Summary

Phase 2 study assessing gefitinib in combination with chemotherapy or antiangiogenic therapy in non-small-cell lung cancer patients with BIM deletion or low EGF…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Caicun Zhou | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: UNKNOWN